Neuland Laboratories delivered impressive results for Q1 FY27, as revenue climbed 119.2% year-on-year to reach ₹641.58 crore, while profit after tax (PAT) skyrocketed 962.4% year-on-year to ₹147.67 crore. Additionally, the firm revealed a new long-term CDMO collaboration with Gland Pharma and gave the green light to a ₹39.8 crore project to expand its capacity. Prominent investor Mukul Agrawal kept his 3.12% shareholding in the company through the quarter ending June 2026.
by shortkt.com✓